Intellia Therapeutics (FRA:38I) Total Long-Term Liabilities : €86.63 Mil (As of Mar. 2025)

View and export this data going back to 2016. Start your Free Trial

What is Intellia Therapeutics Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Intellia Therapeutics's Total Long-Term Liabilities for the quarter that ended in Mar. 2025 was €86.63 Mil.

Intellia Therapeutics Total Long-Term Liabilities Historical Data

The historical data trend for Intellia Therapeutics's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intellia Therapeutics Total Long-Term Liabilities Chart

Intellia Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Long-Term Liabilities

Get a 7-Day Free Trial

69.87

113.62

149.13

124.35

198.84

Intellia Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Long-Term Liabilities	Get a 7-Day Free Trial															115.50	107.19	94.65	198.84	86.63

Intellia Therapeutics Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

Intellia Therapeutics Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Intellia Therapeutics's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Intellia Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intellia Therapeutics Inc (FRA:38I) » Definitions » Total Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

NTLA:USA 0JBU:UK 38I:Germany

Address

40 Erie Street, Suite 130, Cambridge, MA, USA, 02139

Website

https://www.intelliatx.com

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Intellia Therapeutics Headlines

No Headlines